Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy

Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: a National Cohort Study. J Clin Oncol. 2012;30(22):2745–52.

https://doi.org/10.1200/JCO.2011.38.8835 DOI: https://doi.org/10.1200/JCO.2011.38.8835

Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290(4):465–75.

https://doi.org/10.1001/jama.290.4.465 DOI: https://doi.org/10.1001/jama.290.4.465

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–511.

https://doi.org/10.1056/NEJMoa1505949 DOI: https://doi.org/10.1056/NEJMoa1505949

Chamberlin H, Ntentas G, Cutter DJ, Cowan R, Howell S, Hague C, et al. Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000. Acta Oncol. 2025;64:1117–24.

https://doi.org/10.2340/1651-226X.2025.43177 DOI: https://doi.org/10.2340/1651-226X.2025.43177

de Vries S, Schaapveld M, Janus CPM, Daniels LA, Petersen EJ, van der Maazen RWM, et al. Long-term cause-specific mortality in Hodgkin lymphoma patients. J Natl Cancer Inst. 2021;113(6):760–9.

https://doi.org/10.1093/jnci/djaa194 DOI: https://doi.org/10.1093/jnci/djaa194

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–17.

https://doi.org/10.1001/jamainternmed.2015.1180 DOI: https://doi.org/10.1001/jamainternmed.2015.1180

Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol. 2011;29(31):4096–104.

https://doi.org/10.1200/JCO.2011.34.8268 DOI: https://doi.org/10.1200/JCO.2011.34.8268

Glimelius I, Englund A, Rostgaard K, Smedby KE, Eloranta S, de Nully Brown P, et al. Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors – a population-based cohort study from Sweden and Denmark. Cancer Med. 2019;8(10):4918–27.

https://doi.org/10.1002/cam4.2363 DOI: https://doi.org/10.1002/cam4.2363

Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.

https://doi.org/10.1056/NEJMoa1000067 DOI: https://doi.org/10.1056/NEJMoa1000067

Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206.

https://doi.org/10.1200/JCO.2010.29.8018 DOI: https://doi.org/10.1200/JCO.2010.29.8018

Borchmann P, Plutschow A, Kobe C, Greil R, Meissner J, Topp MS, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223–34.

https://doi.org/10.1016/S1470-2045(20)30601-X DOI: https://doi.org/10.1016/S1470-2045(20)30601-X

Molin D, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, et al. Early and intermediate stage Hodgkin’s lymphoma--report from the Swedish National Care Programme. Eur J Haematol. 2003;70(3):172–80.

https://doi.org/10.1034/j.1600-0609.2003.00030.x DOI: https://doi.org/10.1034/j.1600-0609.2003.00030.x

Maraldo MV, Jorgensen M, Brodin NP, Aznar MC, Vogelius IR, Petersen PM, et al. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer. 2014;61(4):717–22.

https://doi.org/10.1002/pbc.24861 DOI: https://doi.org/10.1002/pbc.24861

Aznar MC, Maraldo MV, Schut DA, Lundemann M, Brodin NP, Vogelius IR, et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys. 2015;92(1):169–74.

https://doi.org/10.1016/j.ijrobp.2015.01.013 DOI: https://doi.org/10.1016/j.ijrobp.2015.01.013

Lagerlof I, Holte H, Glimelius I, Bjorkholm M, Enblad G, Erlanson M, et al. No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol. 2020;188(5):685–91.

https://doi.org/10.1111/bjh.16232 DOI: https://doi.org/10.1111/bjh.16232

Lagerlof I, Fohlin H, Enblad G, Glimelius B, Goldkuhl C, Palma M, et al. Limited, but not eliminated, excess long-term morbidity in stage I–IIA Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine and limited-field radiotherapy. J Clin Oncol. 2022;40(13):1487–96.

https://doi.org/10.1200/JCO.21.02407 DOI: https://doi.org/10.1200/JCO.21.02407

Maraldo MV, Brodin NP, Vogelius IR, Aznar MC, Munck Af Rosenschold P, Petersen PM, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;83(4):1232–7.

https://doi.org/10.1016/j.ijrobp.2011.09.020 DOI: https://doi.org/10.1016/j.ijrobp.2011.09.020

Mazonakis M, Lyraraki E, Damilakis J. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma. Med Phys. 2017;44(7):3866–74.

https://doi.org/10.1002/mp.12327 DOI: https://doi.org/10.1002/mp.12327

Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007;110(11):2576–86.

https://doi.org/10.1002/cncr.23081 DOI: https://doi.org/10.1002/cncr.23081

LeMieux MH, Solanki AA, Mahmood U, Chmura SJ, Koshy M. Risk of second malignancies in patients with early-stage classical Hodgkin’s lymphoma treated in a modern era. Cancer Med. 2015;4(4):513–8.

https://doi.org/10.1002/cam4.405 DOI: https://doi.org/10.1002/cam4.405

Baech J, El-Galaly TC, Entrop JP, Glimelius I, Molin D, Godtfredsen SJ, et al. Congestive heart failure after anthracycline-containing treatment for Hodgkin lymphoma: a Swedish matched cohort study. EJHaem. 2024;5(6):1190–200.

https://doi.org/10.1002/jha2.1048 DOI: https://doi.org/10.1002/jha2.1048

Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024;42(16):1903–13.

https://doi.org/10.1200/JCO.23.01386 DOI: https://doi.org/10.1200/JCO.23.01386

Wang Y, Ronckers CM, van Leeuwen FE, Moskowitz CS, Leisenring W, Armstrong GT, et al. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023;29(9):2268–77.

https://doi.org/10.1038/s41591-023-02514-1 DOI: https://doi.org/10.1038/s41591-023-02514-1

Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–32.

https://doi.org/10.1200/JCO.2016.72.1316 DOI: https://doi.org/10.1200/JCO.2016.72.1316

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.

https://doi.org/10.1056/NEJMoa1411087 DOI: https://doi.org/10.1056/NEJMoa1411087

Brockelmann PJ, Buhnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, et al. Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin study group phase II NIVAHL trial. J Clin Oncol. 2023;41(6):1193–9.

https://doi.org/10.1200/JCO.22.02355 DOI: https://doi.org/10.1200/JCO.22.02355

Rechner LA, Maraldo MV, Vogelius IR, Zhu XR, Dabaja BS, Brodin NP, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: the impact of proton therapy and/or deep inspiration breath hold. Radiother Oncol. 2017;125(1):41–7.

https://doi.org/10.1016/j.radonc.2017.07.033 DOI: https://doi.org/10.1016/j.radonc.2017.07.033

Ntentas G, Dedeckova K, Andrlik M, Aznar MC, George B, Kubes J, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most? Pract Radiat Oncol. 2019;9(3):179–87.

https://doi.org/10.1016/j.prro.2019.01.006 DOI: https://doi.org/10.1016/j.prro.2019.01.006

Hoppe BS, Flampouri S, Zaiden R, Slayton W, Sandler E, Ozdemir S, et al. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. Int J Radiat Oncol Biol Phys. 2014;89(5):1053–9.

https://doi.org/10.1016/j.ijrobp.2014.04.029 DOI: https://doi.org/10.1016/j.ijrobp.2014.04.029

Dedeckova K, Andrlik M, Mocikova H, Kaliska L, Zapletalova S, Kubes J, et al. Proton beam therapy for mediastinal Hodgkin lymphoma: a prospective study of clinical efficacy and safety. Radiother Oncol. 2025;208:110931.

https://doi.org/10.1016/j.radonc.2025.110931 DOI: https://doi.org/10.1016/j.radonc.2025.110931

Edvardsson A, Kugele M, Alkner S, Enmark M, Nilsson J, Kristensen I, et al. Comparative treatment planning study for mediastinal Hodgkin’s lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy. Acta Oncol. 2019;58(1):95–104.

https://doi.org/10.1080/0284186X.2018.1512153 DOI: https://doi.org/10.1080/0284186X.2018.1512153

Romero-Exposito M, Sanchez-Nieto B, Riveira-Martin M, Azizi M, Gkavonatsiou A, Munoz I, et al. Individualized evaluation of the total dose received by radiotherapy patients: integrating in-field, out-of-field, and imaging doses. Phys Med. 2025;129:104879.

https://doi.org/10.1016/j.ejmp.2024.104879 DOI: https://doi.org/10.1016/j.ejmp.2024.104879